EyePoint, Inc. announced that its Phase 3 clinical trial for DURAVYU, a treatment for wet age-related macular degeneration, failed to meet the primary endpoint. Following this announcement, EyePoint's stock price dropped over 66%, causing significant losses for investors. A law firm, Kessler Topaz Meltzer & Check, LLP, is investigating potential securities law violations and is offering legal assistance to affected investors. This development raises concerns about the future prospects of EyePoint's treatment and its financial stability.
The global clinical trial supplies market is projected to grow from $5.7 billion in 2025 to $10.7 billion by 2033, at an 8.4% CAGR. This growth is driven by increased R&D investments, rising chronic diseases, and the expansion of biologics, personali...
Starlink Mobile, launched by VEON Ltd. across Ukraine, Kazakhstan, and Bangladesh, has connected over 11 million users in less than a year. The service enables existing 4G phones to access satellite connectivity where terrestrial signals are unavaila...
Medallion Financial Corp. announced it will repurchase $15 million in trust preferred securities from BIMIZCI Fund LLC at 73.66% of face value, costing about $11.05 million plus accrued distributions. This deal includes a five-year standstill agreeme...
Belite Bio, a clinical-stage drug developer focused on retinal diseases, has been approved to move its stock listing from the Nasdaq Capital Market to the Nasdaq Global Select Market, the highest tier on Nasdaq. This uplisting reflects the company's ...
Heineken N.V. has repurchased a total of 8,865,521 shares under the second tranche of its €1.5 billion share buyback program, spending €629.4 million as of October 16, 2026. This includes shares bought on the exchange and from Heineken Holding N.V. T...
